Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462235 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
A Phase 2 study of Gram-negative Bacterial Infection, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT06462235 is a Phase 2 study of Gram-negative Bacterial Infection that is actively recruiting participants, run by Pfizer. The registered enrollment target is 48 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06462235, a Phase 2 study of Gram-negative Bacterial Infection, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria. The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is used to help stop bacteria from being resistant to antibiotics. Antibiotics are medicines that fights bacteria and infections. The study will include newborns and infants up to 9 months of age who are admitted in the hospital. The study is conducted in 2 parts: Part A and Part B. In Part A, all participants will receive a single intravenous (injected directly into a vein) infusion of ATM-AVI. This is to study the safety and effects of a single amount. In Part B, all participants will receive multiple intravenous infusions of ATM-AVI as treatment for a possible or confirmed infection with gram-negative bacteria.
Conditions Studied
Interventions
- DRUG Part A: ATM-AVI Single Dose, Cohorts 1-4
- DRUG Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Study Locations (20)
Kentucky
- Norton Children's Hospital - Louisville
- Novak Center for Children's Health - Louisville
- University of Louisville, Norton Children's Research Institute - Louisville
California
- Children's Hospital of Orange County Southwest Tower - Orange
- Children's Hospital of Orange County - Orange
New Jersey
- Bristol Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital - New Brunswick
- Rutgers University - New Brunswick
Texas
- Memorial Hermann Hospital - Texas Medical Center - Houston
- The University of Texas Health Science Center at Houston - Houston
Buenos Aires
- Sanatorio Sagrado Corazón - Ciudad Autónoma de Buenos Aires
- Clinica Del Niño Y La Madre - Mar del Plata
Colorado
- Children's Hospital Colorado - Aurora
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Massachusetts
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2027-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462235
The ClinicalTrials.gov registry entry for NCT06462235 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gram-negative Bacterial Infection appearing as the primary indexed condition, and to 2 interventions - of which Part A: ATM-AVI Single Dose, Cohorts 1-4 is the first listed.
NCT06462235 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Kentucky, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06462235 about?
NCT06462235 is a clinical study titled "A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)". The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria. The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is u...
What is the current status of trial NCT06462235?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-09-25. Estimated completion is 2027-12-02.
What conditions does trial NCT06462235 study?
This clinical trial studies the following conditions: Gram-negative Bacterial Infection.
What interventions are being tested in trial NCT06462235?
The interventions under investigation include: Part A: ATM-AVI Single Dose, Cohorts 1-4 (DRUG), Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (DRUG).
Who is sponsoring clinical trial NCT06462235?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462235 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.